CL2015003199A1 - Peptidos terapeuticos - Google Patents
Peptidos terapeuticosInfo
- Publication number
- CL2015003199A1 CL2015003199A1 CL2015003199A CL2015003199A CL2015003199A1 CL 2015003199 A1 CL2015003199 A1 CL 2015003199A1 CL 2015003199 A CL2015003199 A CL 2015003199A CL 2015003199 A CL2015003199 A CL 2015003199A CL 2015003199 A1 CL2015003199 A1 CL 2015003199A1
- Authority
- CL
- Chile
- Prior art keywords
- therapeutic peptides
- codifies
- obesity
- understands
- vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Cell Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
POLIPÉPTIDO ANÁLOGO DE PYY; ÁCIDO NUCLEICO QUE LO CODIFICA; VECTOR, CÉLULA HUÉSPED; COMPOSICIÓN FARMACÉUTICA QUE LO COMPRENDE; Y USO PARA TRATAR DESORDEN METABÓLICO, TAL COMO OBESIDAD O DIABETES MELLITUS TIPO 2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361818624P | 2013-05-02 | 2013-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2015003199A1 true CL2015003199A1 (es) | 2016-05-06 |
Family
ID=50842285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2015003199A CL2015003199A1 (es) | 2013-05-02 | 2015-10-30 | Peptidos terapeuticos |
Country Status (20)
Country | Link |
---|---|
US (2) | US20160108098A1 (es) |
EP (1) | EP2992008B1 (es) |
JP (1) | JP2016519130A (es) |
KR (1) | KR20160003848A (es) |
CN (1) | CN105263957A (es) |
AR (1) | AR096162A1 (es) |
AU (1) | AU2014261111B2 (es) |
BR (1) | BR112015027528B1 (es) |
CA (1) | CA2909045C (es) |
CL (1) | CL2015003199A1 (es) |
EA (1) | EA201591839A1 (es) |
ES (1) | ES2732291T3 (es) |
HK (1) | HK1214829A1 (es) |
MX (1) | MX2015015249A (es) |
PE (1) | PE20151808A1 (es) |
RU (1) | RU2015144632A (es) |
SG (1) | SG11201508469YA (es) |
TW (1) | TW201534616A (es) |
UY (1) | UY35548A (es) |
WO (1) | WO2014178018A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3326620T3 (da) | 2010-12-16 | 2020-05-25 | Novo Nordisk As | Faste sammensætninger omfattende en glp-1-agonist og et salt af n-(8-(2- hydroxybenzoyl)amino)caprylsyre |
HUE062740T2 (hu) | 2012-03-22 | 2023-12-28 | Novo Nordisk As | GLP-1 peptidek készítményei és elõállításuk |
CN105263957A (zh) * | 2013-05-02 | 2016-01-20 | 葛兰素史克知识产权开发有限公司 | 治疗肽 |
JP6629198B2 (ja) | 2013-11-15 | 2020-01-15 | ノヴォ ノルディスク アー/エス | 35位にβ−ホモアルギニン置換を有するHPYY(1−36) |
TWI661835B (zh) * | 2013-11-15 | 2019-06-11 | 丹麥商諾佛 儂迪克股份有限公司 | 選擇性pyy化合物及其用途 |
WO2016124687A1 (en) * | 2015-02-04 | 2016-08-11 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
AU2016275735B2 (en) | 2015-06-12 | 2020-02-06 | Novo Nordisk A/S | Selective PYY compounds and uses thereof |
TW201726706A (zh) * | 2015-12-28 | 2017-08-01 | 出光興產股份有限公司 | 胜肽標記及含有其之附加標記的蛋白質 |
JOP20190095A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y |
WO2018165462A1 (en) | 2017-03-08 | 2018-09-13 | Intarcia Therapeutics, Inc | Apparatus and methods for administration of a nauseogenic compound from a drug delivery device |
CN111683676B (zh) | 2018-02-02 | 2024-06-18 | 诺和诺德股份有限公司 | 包含glp-1激动剂、n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐和润滑剂的固体组合物 |
US11780900B2 (en) | 2018-04-25 | 2023-10-10 | Janssen Sciences Ireland Unlimited Company | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof |
TW202208410A (zh) * | 2018-11-01 | 2022-03-01 | 美商美國禮來大藥廠 | 蛋白質酪胺酸-酪胺酸類似物及其使用方法 |
JOP20220110A1 (ar) | 2019-11-11 | 2023-01-30 | Boehringer Ingelheim Int | ناهضات مستقبل npy2 |
WO2021113524A2 (en) * | 2019-12-04 | 2021-06-10 | The Scripps Research Institute | Glp2 receptor agonists and methods of use |
KR20230039601A (ko) * | 2020-04-17 | 2023-03-21 | 아이투오 테라퓨틱스, 인코포레이티드 | 장기간 작용하는 펩티드 티로신 티로신(pyy) 유사체 및 사용 방법 |
KR20230045088A (ko) | 2020-08-07 | 2023-04-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 가용성 npy2 수용체 작용제 |
US20240091318A1 (en) | 2022-08-18 | 2024-03-21 | Boehringer Ingelheim International Gmbh | Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists |
CN117603364A (zh) * | 2022-09-30 | 2024-02-27 | 广西医科大学附属肿瘤医院 | 一类GLP-1/glucagon/Y2受体三重激动剂及其应用 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
DK134189D0 (da) | 1989-03-20 | 1989-03-20 | Nordisk Gentofte | Insulinforbindelser |
EP0512042B1 (en) | 1990-01-24 | 1998-04-08 | BUCKLEY, Douglas I. | Glp-1 analogs useful for diabetes treatment |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5612052A (en) | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
US6413539B1 (en) | 1996-10-31 | 2002-07-02 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
US5612051A (en) | 1995-11-17 | 1997-03-18 | Yue; Samuel K. | Method of treating involuntary muscle dysfunction with relaxin hormone |
ATE417622T1 (de) | 1996-08-08 | 2009-01-15 | Amylin Pharmaceuticals Inc | Regulation gastrointestinaler beweglichkeit |
PT1019077E (pt) | 1997-08-08 | 2008-02-21 | Amylin Pharmaceuticals Inc | Novos compostos agonistas de exendina |
US6117949A (en) | 1998-10-01 | 2000-09-12 | Macromed, Inc. | Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
US6004573A (en) | 1997-10-03 | 1999-12-21 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
BR9814189A (pt) | 1997-11-14 | 2000-10-03 | Amylin Pharmaceuticals Inc | "compostos agonistas da exendina" |
MXPA00004670A (es) | 1997-11-14 | 2003-07-14 | Amylin Pharmaceuticals Inc | Compuestos agonistas de exendina novedosos. |
JP4677095B2 (ja) | 1998-02-13 | 2011-04-27 | アミリン・ファーマシューティカルズ,インコーポレイテッド | エキセンジンおよびglp−1の変力および利尿効果 |
WO1999043708A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
US6669961B2 (en) | 2000-08-15 | 2003-12-30 | Board Of Trustees Of University Of Illinois | Microparticles |
US7459432B2 (en) * | 2001-09-24 | 2008-12-02 | Imperial College Innovations Ltd. | Modification of feeding behavior |
EP2335715A3 (en) * | 2004-02-11 | 2013-12-18 | Amylin Pharmaceuticals, LLC | Pancreatic polypeptide family motifs and polypeptides comprising the same |
CA2577821A1 (en) * | 2004-09-24 | 2006-04-06 | Merck & Co., Inc. | Combination therapy for the treatment of obesity |
KR101272402B1 (ko) * | 2004-12-13 | 2013-06-10 | 아스트라제네카 파마수티컬스 엘피 | 췌장 폴리펩티드 족 모티프, 폴리펩티드 및 이를 포함하는방법 |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
GB0504857D0 (en) * | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
EA200870365A1 (ru) * | 2006-03-23 | 2009-02-27 | Амилин Фармасьютикалз, Инк. | Эндотелин и агонисты рецепторов к эндотелину в лечении заболеваний обмена веществ |
MX2012003939A (es) | 2009-09-30 | 2012-07-30 | Glaxo Group Ltd | Fusiones y conjugados de farmaco. |
WO2011050008A2 (en) | 2009-10-19 | 2011-04-28 | Amylin Pharmaceuticals, Inc. | Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders |
GB201001333D0 (en) * | 2010-01-27 | 2010-03-17 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
JO3131B1 (ar) | 2010-04-27 | 2017-09-20 | Glaxosmithkline Llc | مركبات كيميائية |
US8927687B2 (en) * | 2010-07-09 | 2015-01-06 | Amylin Pharmaceuticals, Llc | Microcrystalline Y receptor agonists |
GB201101459D0 (en) | 2011-01-27 | 2011-03-16 | Imp Innovations Ltd | Novel compounds and thier effects on fedding behaviour |
CN105263957A (zh) * | 2013-05-02 | 2016-01-20 | 葛兰素史克知识产权开发有限公司 | 治疗肽 |
TWI661835B (zh) * | 2013-11-15 | 2019-06-11 | 丹麥商諾佛 儂迪克股份有限公司 | 選擇性pyy化合物及其用途 |
-
2014
- 2014-04-30 CN CN201480024836.3A patent/CN105263957A/zh active Pending
- 2014-04-30 JP JP2016511159A patent/JP2016519130A/ja active Pending
- 2014-04-30 AR ARP140101793A patent/AR096162A1/es unknown
- 2014-04-30 ES ES14727241T patent/ES2732291T3/es active Active
- 2014-04-30 EA EA201591839A patent/EA201591839A1/ru unknown
- 2014-04-30 MX MX2015015249A patent/MX2015015249A/es unknown
- 2014-04-30 AU AU2014261111A patent/AU2014261111B2/en active Active
- 2014-04-30 PE PE2015002329A patent/PE20151808A1/es not_active Application Discontinuation
- 2014-04-30 WO PCT/IB2014/061123 patent/WO2014178018A1/en active Application Filing
- 2014-04-30 TW TW103115659A patent/TW201534616A/zh unknown
- 2014-04-30 RU RU2015144632A patent/RU2015144632A/ru not_active Application Discontinuation
- 2014-04-30 CA CA2909045A patent/CA2909045C/en active Active
- 2014-04-30 KR KR1020157034300A patent/KR20160003848A/ko not_active Application Discontinuation
- 2014-04-30 US US14/888,085 patent/US20160108098A1/en not_active Abandoned
- 2014-04-30 BR BR112015027528-1A patent/BR112015027528B1/pt active IP Right Grant
- 2014-04-30 US US14/265,831 patent/US9441023B2/en active Active
- 2014-04-30 EP EP14727241.3A patent/EP2992008B1/en active Active
- 2014-04-30 UY UY0001035548A patent/UY35548A/es not_active Application Discontinuation
- 2014-04-30 SG SG11201508469YA patent/SG11201508469YA/en unknown
-
2015
- 2015-10-30 CL CL2015003199A patent/CL2015003199A1/es unknown
-
2016
- 2016-03-09 HK HK16102709.0A patent/HK1214829A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2992008B1 (en) | 2019-04-10 |
TW201534616A (zh) | 2015-09-16 |
PE20151808A1 (es) | 2015-12-16 |
MX2015015249A (es) | 2016-02-09 |
EP2992008A1 (en) | 2016-03-09 |
KR20160003848A (ko) | 2016-01-11 |
JP2016519130A (ja) | 2016-06-30 |
ES2732291T3 (es) | 2019-11-21 |
CA2909045C (en) | 2022-12-06 |
WO2014178018A1 (en) | 2014-11-06 |
AR096162A1 (es) | 2015-12-09 |
AU2014261111A1 (en) | 2015-11-19 |
US20140329742A1 (en) | 2014-11-06 |
CN105263957A (zh) | 2016-01-20 |
RU2015144632A (ru) | 2017-06-07 |
BR112015027528A2 (pt) | 2017-12-05 |
UY35548A (es) | 2014-11-28 |
EA201591839A1 (ru) | 2016-05-31 |
HK1214829A1 (zh) | 2016-08-05 |
CA2909045A1 (en) | 2014-11-06 |
AU2014261111B2 (en) | 2017-03-16 |
US20160108098A1 (en) | 2016-04-21 |
BR112015027528B1 (pt) | 2023-02-14 |
SG11201508469YA (en) | 2015-11-27 |
US9441023B2 (en) | 2016-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015003199A1 (es) | Peptidos terapeuticos | |
CL2014003465A1 (es) | Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer. | |
BR112017001183A2 (pt) | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado | |
PH12016501151A1 (en) | Nrf2 regulators | |
AR092589A1 (es) | Analogos de glucagon | |
MX371187B (es) | Péptidos terapéuticos. | |
CL2014001994A1 (es) | Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido. | |
MX368435B (es) | Analogos del glucagon. | |
BR112013032717A2 (pt) | coagonistas do receptor de glucagon/glp-1 | |
UY33462A (es) | Analogos de glucagon | |
GT201500051A (es) | Inhibidores de glucosilceramida sintasa | |
MX2019006260A (es) | Agonistas de glucagon/peptido similar al glucagon de tipo 1 (glp-1) para el tratamiendo de la obesidad. | |
BR112014032938A2 (pt) | uso de peptídeos de glp-1 de longa ação | |
MX368436B (es) | Analogos de glucagon acilados. | |
UY36561A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
BR112016016290A2 (pt) | Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina | |
CL2013002898A1 (es) | Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer. | |
BR112019011065A2 (pt) | métodos para determinação da dosagem de células t car | |
BR112014000466A2 (pt) | polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos | |
CL2015000532A1 (es) | Molécula de enlace a interleuquina 18 (il-18); anticuerpo; polinucleótido que lo codifica; vector; célula huésped; composición farmacéutica; uso para tratar sarcoidosis y otras inmunodeficiencias; y kit de diagnóstico. | |
CL2014002348A1 (es) | Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado. | |
CL2016000026A1 (es) | Nuevos derivados de azabencimidazol | |
CL2015000976A1 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados. | |
CL2014003339A1 (es) | Anticuerpo humanizado anti-trka con propiedades inhibitorias mejoradas; composición que lo comprende; y uso para tratar el dolor. | |
CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. |